Journal
PSYCHOPHARMACOLOGY
Volume 192, Issue 4, Pages 547-553Publisher
SPRINGER
DOI: 10.1007/s00213-007-0748-5
Keywords
Alzheimer's disease; platelet; APP ratio; mild cognitive impairment; Western blot APP; membrane fluidity
Categories
Funding
- Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [02/13633-7] Funding Source: FAPESP
Ask authors/readers for more resources
Rationale Previous studies have implicated platelet amyloid precursor protein (APP) as a candidate biomarker for Alzheimer's disease (AD). Platelets contain more than 95% of the circulating APP and enclose the enzymatic machinery for the APP metabolism yielding both soluble APP and amyloid- beta peptides. Objectives The objective of this study is to compare the ratio of 130- to 110- kDa fragments of APP in platelets from patients with AD, mild cognitive impairment (MCI), and elderly controls. Materials and methods After subjects were grouped according to diagnosis, APP ratio in platelets was evaluated by means of Western blot analysis. Results The APP ratio was significantly lower in AD patients (1.01 +/- 0.21) as compared to controls (1.24 +/- 0.21, p= 0.001) and MCI patients (1.18 +/- 0.21, p= 0.027), but no significant differences were found between MCI and controls (p= 0.904). In addition, we found positive correlations between the APP ratio and 1,6- diphenyl- 1,3,5-hexatriene anisotropy (r= 0.3, p= 0.01), as well as with certain parameters of cognitive decline, namely, the minimental state examination score (r= 0.33, p= 0.003), the total Cambridge cognitive test (CAMCOG) score (r= 0.37, p= 0.001), and the score on the memory subscale of the CAMCOG (r= 0.38, p= 0.001). Conclusions The pattern of platelet APP fragments was altered in patients with AD but not in patients with MCI. The alteration of APP fragments was correlated with membrane fluidity and the cognitive decline.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available